Translational regulation as a novel mechanism for the development of cellular drug resistance

Cancer and Metastasis Reviews

Volumn 20, Issue 1-2, 2001, Pages 33-41

  Schmitz, John C ^a   Liu, Jun ^a   Lin, Xiukun ^a   Chen, Tian Min ^a   Yan, Wu ^a   Tai, Ningwen ^a   Gollerkeri, Ashwin ^a   Chu, Edward ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Dihydrofolate reductase; Drug resistance; p53 translational regulation; Thymidylate synthase

Indexed keywords

DIHYDROFOLATE REDUCTASE; PROTEIN P53; THYMIDYLATE SYNTHASE;

ARTICLE; AUTOREGULATION; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CHEMOSENSITIVITY; ENZYME ANALYSIS; ENZYME MECHANISM; MODEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRANSLATION REGULATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; PROTEIN BIOSYNTHESIS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035695106     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013100306315     Document Type: Article

References (69)

1. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate
2. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
3. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
4. p53 status and the efficacy of cancer therapy in vivo
5. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
6. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
7. DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers
8. Lynch syndrome: Genetics, natural history, genetic counseling, and prevention
9. The role of DNA mismatch repair in drug resistance
10. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
11. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin
12. Origins and targets of translational control
13. Folates in pyrimidine nucleotide biosynthesis
14. The catalytic mechanism and structure of thymidylate synthase
15. Thymidylate synthase: A target enzyme in cancer chemotherapy
16. The effect of methotrexate on enzyme induced following partial hepatectomy
17. Effect of methotrexate on thymidylate synthetase in cultured parenchymal cells isolated from regenerating rat liver
18. In vivo kinetics of thymidylate synthase inhibition in 5-fluororuacil-sensitive and resistant murine colon adenocarcinoma
19. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil
20. 5-Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
21. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murin colon tumors
22. The thymidylate synthase inhibitor, ICI D 1694, overcomes translational detainment of the enzyme
23. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line
24. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma
25. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues
26. Sequence-specific interaction of R17 coat protein with its ribonucleic acid binding site
27. Nucleotide sequence at the binding site for coat protein on RNA of bacteriophage R17
28. Bacteriophage T4 regA protein binds to mRNAs and prevents translation initiation
29. DNA polymerase of bacteriophage T4 is an autogenous translational repressor
30. Posttranscriptional regulatory mechanisms in Escherichia coli
31. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro
32. Translational regulation of the synthesis of dihydrofolate reductase
33. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region
34. Negative feedback regulation of wild-type p53 synthesis
35. Translational regulation of human p53 expression
36. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase
37. Identification of an RNA binding site for human thymidylate synthase
38. Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA
39. The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA
40. Antifolates
41. Folate antagonists
42. Dihydrofolate reducrase as a therapeutic target
43. Studies on normal and leukemic leucocytes. IV. Tetrahydrofolate-dependent enzyme systems and dihydrofolate reductase
44. The 'induction' of leukocyte and erythrocyte and dihydrofolate reductase by methotrexate. II. Clinical and pharmacological studies
45. Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate
46. The intracellular content of dihydrofolate reductase: Possibilities for control and implications for chemotherapy
47. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells
48. Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene
49. Determinants of trimetrexate lethality in human colon cancer cells
50. Translational regulation of DHFR expression in human colon cancer RKO cells
51. Cis-regulatory elements at the 5′UTR regulates the expression of dihydrofolate reductase (DHFR) at the translational level
52. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
53. Clinical implications of the p53 tumor-suppressor gene
54. p53, the cellular gatekeeper for growth and division
55. p53: Puzzle and paradigm
56. p53 function and dysfunction
57. WAF1, a potential mediator of p53 tumor suppression
58. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
59. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
60. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
61. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
62. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage
63. DNA damage activates p53 through a phosphorylation-acetylation cascade
64. Participation of p53 protein in the cellular response to DNA damage
65. Induction of cellular p53 activity by DNA-damaging agents and growth arrest
66. Participation of the human p53 3′UTR in translational repression and activation following gamma-irradiation
67. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
68. Regulation of p53 expression by thymidylate synthase
69. Translational regulation of 5-FU induced p53 expression in human cancer RKO cells